$PRTA
PROTHENA CORP PUBLIC LTD CO

2021 Q4 Form 10-Q Financial Statement

#000155905321000045 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $1.172M $139.2M $157.0K
YoY Change 225.56% 88545.86% -23.41%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.21M $11.96M $9.400M
YoY Change 23.17% 27.18% 8.17%
% of Gross Profit
Research & Development $22.06M $17.99M $21.61M
YoY Change 6.25% -16.72% 73.03%
% of Gross Profit
Depreciation & Amortization $240.0K $300.0K $400.0K
YoY Change -33.33% -25.0% 0.0%
% of Gross Profit
Operating Expenses $34.26M $29.95M $31.00M
YoY Change 11.73% -3.41% 46.4%
Operating Profit $109.2M -$30.85M
YoY Change -454.1% 47.08%
Interest Expense $12.00K $11.00K $40.00K
YoY Change 20.0% -72.5% -98.03%
% of Operating Profit 0.01%
Other Income/Expense, Net -$16.00K -$31.00K $54.00K
YoY Change -77.14% -157.41% -97.29%
Pretax Income -$33.10M $109.2M -$30.79M
YoY Change 9.01% -454.62% 62.23%
Income Tax $83.00K -$51.00K -$215.0K
% Of Pretax Income -0.05%
Net Earnings -$33.18M $109.2M -$30.58M
YoY Change 8.02% -457.28% 57.22%
Net Earnings / Revenue -2830.97% 78.5% -19475.8%
Basic Earnings Per Share $2.39 -$0.77
Diluted Earnings Per Share -$711.3K $2.13 -$0.77
COMMON SHARES
Basic Shares Outstanding 46.59M shares 45.63M shares 39.92M shares
Diluted Shares Outstanding 51.21M shares 39.92M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $579.1M $600.1M $314.5M
YoY Change 96.04% 90.81% -19.42%
Cash & Equivalents $579.1M $600.1M $314.5M
Short-Term Investments
Other Short-Term Assets $5.715M $7.353M $6.000M
YoY Change 46.54% 22.55% 90.6%
Inventory
Prepaid Expenses
Receivables $0.00 $79.00K $22.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $584.8M $607.5M $320.5M
YoY Change 95.4% 89.57% -21.68%
LONG-TERM ASSETS
Property, Plant & Equipment $2.012M $1.944M $2.899M
YoY Change -21.13% -32.94% -31.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.999M $1.808M $327.0K
YoY Change 500.3% 452.91% -51.7%
Total Long-Term Assets $24.56M $25.17M $35.30M
YoY Change -27.11% -28.68% -15.33%
TOTAL ASSETS
Total Short-Term Assets $584.8M $607.5M $320.5M
Total Long-Term Assets $24.56M $25.17M $35.30M
Total Assets $609.4M $632.7M $355.8M
YoY Change 83.01% 77.83% -21.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.691M $3.483M $2.810M
YoY Change -10.35% 23.95% 16.21%
Accrued Expenses $20.94M $17.39M $17.50M
YoY Change 2.12% -0.62% 35.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $33.45M $29.20M $21.72M
YoY Change 29.42% 34.43% -31.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $553.0K $553.0K $553.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $109.9M $113.0M $124.5M
YoY Change -10.76% -9.25% -4.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.45M $29.20M $21.72M
Total Long-Term Liabilities $109.9M $113.0M $124.5M
Total Liabilities $143.3M $142.2M $146.3M
YoY Change -3.79% -2.76% -9.55%
SHAREHOLDERS EQUITY
Retained Earnings -$716.1M -$682.9M -$752.3M
YoY Change -8.55% -9.23% 15.68%
Common Stock $466.0K $465.0K $399.0K
YoY Change 16.79% 16.54% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $466.0M $490.5M $209.5M
YoY Change
Total Liabilities & Shareholders Equity $609.4M $632.7M $355.8M
YoY Change 83.01% 77.83% -21.09%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$33.18M $109.2M -$30.58M
YoY Change 8.02% -457.28% 57.22%
Depreciation, Depletion And Amortization $240.0K $300.0K $400.0K
YoY Change -33.33% -25.0% 0.0%
Cash From Operating Activities -$22.46M $112.1M -$19.41M
YoY Change 17.64% -677.59% 117.11%
INVESTING ACTIVITIES
Capital Expenditures -$319.0K -$208.0K -$80.00K
YoY Change 538.0% 160.0% -68.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$319.0K -$208.0K -$80.00K
YoY Change 538.0% 160.0% -68.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.773M 87.01M 70.00K
YoY Change 124204.29%
NET CHANGE
Cash From Operating Activities -22.46M 112.1M -19.41M
Cash From Investing Activities -319.0K -208.0K -80.00K
Cash From Financing Activities 1.773M 87.01M 70.00K
Net Change In Cash -21.00M 198.9M -19.42M
YoY Change 9.74% -1124.28% 111.32%
FREE CASH FLOW
Cash From Operating Activities -$22.46M $112.1M -$19.41M
Capital Expenditures -$319.0K -$208.0K -$80.00K
Free Cash Flow -$22.14M $112.3M -$19.33M
YoY Change 16.28% -681.06% 122.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001559053
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 prta Buildtosuit Lease Termof Contract
BuildtosuitLeaseTermofContract
P7Y9M30D
CY2020Q3 prta Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision
SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
0 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35676
dei Entity Registrant Name
EntityRegistrantName
PROTHENA CORPORATION PUBLIC LIMITED COMPANY
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1111119
dei Entity Address Address Line1
EntityAddressAddressLine1
77 Sir John Rogerson’s Quay, Block C
dei Entity Address Address Line2
EntityAddressAddressLine2
Grand Canal Docklands
dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin 2,
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
D02 VK60,
dei Entity Address Country
EntityAddressCountry
IE
dei Country Region
CountryRegion
353
dei City Area Code
CityAreaCode
1
dei Local Phone Number
LocalPhoneNumber
236-2500
dei Security12b Title
Security12bTitle
Ordinary Shares, par value $0.01 per share
dei Trading Symbol
TradingSymbol
PRTA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46593782 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
600098000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
295380000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
79000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7353000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2537000 USD
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 USD
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1352000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
607530000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
299284000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2551000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13567000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17811000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
6503000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
11644000 USD
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1352000 USD
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1352000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1808000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
333000 USD
CY2021Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
25174000 USD
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
33691000 USD
CY2021Q3 us-gaap Assets
Assets
632704000 USD
CY2020Q4 us-gaap Assets
Assets
332975000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3483000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4117000 USD
CY2021Q3 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
5315000 USD
CY2020Q4 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
9044000 USD
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0 USD
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
36000 USD
CY2021Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7205000 USD
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5831000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5512000 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7367000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7139000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
29201000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25848000 USD
CY2021Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
104557000 USD
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
110242000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7922000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12326000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
553000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
553000 USD
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
113032000 USD
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
123121000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
142233000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
148969000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2020Q4 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2021Q3 prta Deferred Shares Value
DeferredSharesValue
0 USD
CY2020Q4 prta Deferred Shares Value
DeferredSharesValue
0 USD
CY2020Q4 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2021Q3 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2020Q4 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2021Q3 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2020Q4 prta Deferred Shares Share Issued
DeferredSharesShareIssued
0 shares
CY2021Q3 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2021Q3 prta Deferred Shares Share Issued
DeferredSharesShareIssued
0 shares
CY2020Q4 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
465000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
399000 USD
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46533247 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46533247 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39921413 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39921413 shares
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1172881000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
966636000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-682875000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-783029000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
490471000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
184006000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
632704000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
332975000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
139174000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
157000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
199405000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
493000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17992000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21605000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60226000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54124000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11955000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9398000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34112000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28795000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.02
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
29947000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
31003000 USD
us-gaap Operating Expenses
OperatingExpenses
94338000 USD
us-gaap Operating Expenses
OperatingExpenses
82919000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
109227000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30846000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
105067000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-82426000 USD
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
11000 USD
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
43000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
30000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1359000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-80000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
54000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-50000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1362000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
109196000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30792000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
105017000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-81064000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-51000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-215000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4863000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-636000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
109247000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-30577000 USD
us-gaap Net Income Loss
NetIncomeLoss
100154000 USD
us-gaap Net Income Loss
NetIncomeLoss
-80428000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.39
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.13
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.02
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45626000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39917000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43422000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39912000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51205000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39917000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47196000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39912000 shares
us-gaap Net Income Loss
NetIncomeLoss
100154000 USD
us-gaap Net Income Loss
NetIncomeLoss
-80428000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
875000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1152000 USD
prta Sharebased Compensationnonrestructuring
SharebasedCompensationnonrestructuring
17771000 USD
prta Sharebased Compensationnonrestructuring
SharebasedCompensationnonrestructuring
16806000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
5141000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1568000 USD
prta Amortizationofrightofuseasset
Amortizationofrightofuseasset
4244000 USD
prta Amortizationofrightofuseasset
Amortizationofrightofuseasset
4077000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
64000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-46000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6291000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1244000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4202000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3669000 USD
prta Increase Decreasein Operating Lease Liability
IncreaseDecreaseinOperatingLeaseLiability
4085000 USD
prta Increase Decreasein Operating Lease Liability
IncreaseDecreaseinOperatingLeaseLiability
3778000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1520000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
115063000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61268000 USD
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
256000 USD
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
145000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-256000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-145000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13694000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
215000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
188559000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
215000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
303366000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-61198000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298084000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
378427000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
601450000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
317229000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
568000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
672000 USD
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
11000 USD
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
37000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
600098000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
314525000 USD
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 USD
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1352000 USD
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1352000 USD
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1352000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
601450000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
317229000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
288207000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6055000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6055000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4132000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
109247000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
490471000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
234444000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5583000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-30577000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
209514000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
184006000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17771000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13694000 USD
us-gaap Net Income Loss
NetIncomeLoss
100154000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
490471000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
272921000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16806000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
215000 USD
us-gaap Net Income Loss
NetIncomeLoss
-80428000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
209514000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-682900000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
600100000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Concentration of Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The receivables recorded in the Condensed Consolidated Balance Sheet as of September 30, 2021 include amounts due from a Novo Nordisk entity located in Denmark. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, $1.9 million of the Company’s property and equipment, net were held in the U.S. and a nominal amount were in Ireland. As of December 31, 2020, $2.6 million of the Company's property and equipment, net were held in the U.S. and nominal were in Ireland. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</span></div>
CY2021Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
9464000 USD
CY2020Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
9343000 USD
CY2021Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1394000 USD
CY2020Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1278000 USD
CY2021Q3 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
1454000 USD
CY2020Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
1423000 USD
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12312000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12044000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10368000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9493000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1944000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2551000 USD
CY2021Q3 us-gaap Depreciation
Depreciation
300000 USD
us-gaap Depreciation
Depreciation
900000 USD
CY2020Q3 us-gaap Depreciation
Depreciation
400000 USD
us-gaap Depreciation
Depreciation
1200000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6246000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5927000 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
693000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
696000 USD
CY2021Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
428000 USD
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
516000 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7367000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7139000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
109247000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-30577000 USD
us-gaap Net Income Loss
NetIncomeLoss
100154000 USD
us-gaap Net Income Loss
NetIncomeLoss
-80428000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45626000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39917000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43422000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39912000 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
5579000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
0 shares
us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
3774000 shares
us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
0 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51205000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39917000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47196000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39912000 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.39
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.02
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.13
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.02
CY2016Q1 prta Operating Lease Area
OperatingLeaseArea
128751 sqft
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M
CY2016Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-12-31
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
39200000 USD
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1600000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
4800000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1600000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
4800000 USD
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1500000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
4600000 USD
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1500000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
4500000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0425
CY2016Q4 prta Operating Leases Improvement Allowance
OperatingLeasesImprovementAllowance
14200000 USD
CY2018Q3 prta Operating Leases Sublease Rentals Areaof Sublease Rental
OperatingLeasesSubleaseRentalsAreaofSubleaseRental
46641 sqft
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
700000 USD
us-gaap Sublease Income
SubleaseIncome
2200000 USD
CY2020Q3 us-gaap Sublease Income
SubleaseIncome
700000 USD
us-gaap Sublease Income
SubleaseIncome
2200000 USD
CY2018Q3 prta Subleaserentals Annual Base Rent Initial Amount
SubleaserentalsAnnualBaseRentInitialAmount
2700000 USD
CY2018Q3 prta Operating Leases Sublease Rentals Percent Annual Rent Increase
OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease
0.035
CY2018Q3 prta Operating Leases Sublease Rentals Termof Contract
OperatingLeasesSubleaseRentalsTermofContract
P5Y2M12D
CY2018Q3 prta Operating Leases Sublease Rentals Percentof Rental Gain Attributableto Sublandlord
OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord
0.50
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1604000 USD
CY2021Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
752000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6424000 USD
CY2021Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
3047000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6535000 USD
CY2021Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
3019000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 USD
CY2021Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
0 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14563000 USD
CY2021Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
6818000 USD
CY2021Q3 prta Lessee Operating Lease Liability Nominal Payments
LesseeOperatingLeaseLiabilityNominalPayments
110000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
700000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13753000 USD
CY2021Q3 us-gaap Purchase Obligation
PurchaseObligation
10800000 USD
CY2021Q3 us-gaap Contractual Obligation
ContractualObligation
500000 USD
CY2021Q3 us-gaap Purchase Obligation
PurchaseObligation
10823000 USD
CY2021Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
10823000 USD
CY2021Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
0 USD
CY2021Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
0 USD
CY2021Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
0 USD
CY2021Q3 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
0 USD
CY2021Q3 prta Purchase Obligation To Be Paid After Year Four
PurchaseObligationToBePaidAfterYearFour
0 USD
CY2021Q3 prta Purchaseand Contractual Obligation Total
PurchaseandContractualObligationTotal
11313000 USD
CY2021Q3 prta Purchaseand Contractual Obligation Remainderof Fiscal Year
PurchaseandContractualObligationRemainderofFiscalYear
10933000 USD
CY2021Q3 prta Purchase And Contractual Obligation Due In Year One
PurchaseAndContractualObligationDueInYearOne
55000 USD
CY2021Q3 prta Purchaseand Contractual Obligation Duein Second Year
PurchaseandContractualObligationDueinSecondYear
55000 USD
CY2021Q3 prta Purchaseand Contractual Obligation Duein Third Year
PurchaseandContractualObligationDueinThirdYear
45000 USD
CY2021Q3 prta Purchaseand Contractual Obligation Duein Fourth Year
PurchaseandContractualObligationDueinFourthYear
45000 USD
CY2021Q3 prta Purchase And Contractual Obligation Due After Fourth Year
PurchaseAndContractualObligationDueAfterFourthYear
180000 USD
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46533247 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46533247 shares
prta Numberof Votes
NumberofVotes
1 vote
CY2021Q3 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2021Q3 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2021Q3 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
176000 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
147000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3323477 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1372587 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1865950 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3152827 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8649897 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.97
CY2021Q1 prta Number Of Ordinary Shares Tendered For Exchange Under The Option Exchage
NumberOfOrdinarySharesTenderedForExchangeUnderTheOptionExchage
2100000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1400000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
22.85
CY2021Q1 prta Share Based Compensation Arrangement By Share Based Payment Award Options Minimum Exchange Threshold Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumExchangeThresholdExercisePrice
17.63
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
49300000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y18D
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
6055000 USD
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
5583000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
17771000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
16806000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.828
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.796
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.816
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.811
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.003
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
45.53
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.22
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8744765 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.42
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M8D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4656000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3323477 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
25.19
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
946660 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
14.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
467697 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
23.62
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2003988 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
40.98
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8649897 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M4D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
460683000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8228512 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y1M9D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
439882000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
3433364 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M
CY2021Q3 prta Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions
195691000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1372587 shares
CY2021Q1 prta Share Based Compensation Arrangement By Share Based Payment Award Unvested Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedOptionsForfeituresInPeriod
179959 shares
CY2021Q1 prta Share Based Compensation Arrangement By Share Based Payment Award Unvested Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedOptionsExpirationsInPeriod
1934446 shares
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-51000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4900000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-215000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-636000 USD
CY2021Q3 prta Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision
SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
-400000 USD
prta Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision
SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
37000 USD
prta Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision
SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
100000 USD
prta Deferred Tax Assets Period Increase Decrease
DeferredTaxAssetsPeriodIncreaseDecrease
5100000 USD
prta Deferred Tax Assets Period Increase Decrease Tax Cuts And Jobs Act
DeferredTaxAssetsPeriodIncreaseDecreaseTaxCutsAndJobsAct
3500000 USD
prta Deferred Tax Asset Period Increase Decrease American Rescue Plan Act
DeferredTaxAssetPeriodIncreaseDecreaseAmericanRescuePlanAct
700000 USD

Files In Submission

Name View Source Status
0001559053-21-000045-index-headers.html Edgar Link pending
0001559053-21-000045-index.html Edgar Link pending
0001559053-21-000045.txt Edgar Link pending
0001559053-21-000045-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
prta-20210930.htm Edgar Link pending
prta-20210930.xsd Edgar Link pending
prta-20210930_cal.xml Edgar Link unprocessable
prta-20210930_def.xml Edgar Link unprocessable
prta-20210930_htm.xml Edgar Link completed
prta-20210930_lab.xml Edgar Link unprocessable
prta-20210930_pre.xml Edgar Link unprocessable
prta2021q310-qxex311.htm Edgar Link pending
prta2021q310-qxex312.htm Edgar Link pending
prta2021q310-qxex321.htm Edgar Link pending
prta2021q3xex101tenthamend.htm Edgar Link pending
prta2021q3xex102selkoearco.htm Edgar Link pending
prta2021q3xex103prothenaxr.htm Edgar Link pending
prta2021q3xex104prothenaxn.htm Edgar Link pending
prta2021q3xex105prothenaxb.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending